Silvercrest Asset Management Group LLC Protagonist Therapeutics, Inc Transaction History
Silvercrest Asset Management Group LLC
- $14.3 Billion
- Q3 2024
A detailed history of Silvercrest Asset Management Group LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Silvercrest Asset Management Group LLC holds 85,254 shares of PTGX stock, worth $3.26 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
85,254
Previous 191,168
55.4%
Holding current value
$3.26 Million
Previous $6.62 Million
42.16%
% of portfolio
0.03%
Previous 0.05%
Shares
15 transactions
Others Institutions Holding PTGX
# of Institutions
247Shares Held
56.7MCall Options Held
76.3KPut Options Held
114K-
Farallon Capital Management LLC San Francisco, CA5.86MShares$224 Million1.32% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$220 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.43MShares$207 Million3.89% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.22MShares$161 Million0.0% of portfolio
-
State Street Corp Boston, MA3.18MShares$122 Million0.01% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $1.88B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...